Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.613 USD -6.03%
Market Cap: 4.8B USD
Have any thoughts about
Alkermes Plc?
Write Note

Alkermes Plc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alkermes Plc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Alkermes Plc
NASDAQ:ALKS
EPS (Diluted)
$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
10%
Prothena Corporation PLC
NASDAQ:PRTA
EPS (Diluted)
-$2
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
-30%
No Stocks Found

Alkermes Plc
Glance View

Market Cap
4.8B USD
Industry
Biotechnology

Alkermes Plc, an Irish biopharmaceutical company, has carved its niche at the intersection of neuroscience and oncology, a strategic pivot that underscores its commitment to addressing unmet medical needs. The firm's focus lies in the development of innovative pharmaceuticals that offer hope and efficacy where other treatments may fall short. These include proprietary products as well as collaborations with more established pharmaceutical entities. At the heart of Alkermes' operations is its R&D engine, which drives the development of cutting-edge treatments leveraging the company's proprietary technology platforms. This not only underpins its internal drug development pipeline but also enhances its value proposition in collaborations with partner companies, fostering a symbiotic environment where innovation and mutual benefit intersect. The way Alkermes generates revenue is multifaceted, reflecting its dynamic business model. The company earns through product sales from its proprietary medicines, which are tailored for chronic diseases such as schizophrenia, addiction, and multiple sclerosis. Moreover, a significant portion of its income is derived from strategic collaborations and royalty agreements, where it grants larger pharmaceutical companies access to its technology platforms or the commercial rights to certain drug formulations. These alliances often entail milestone-based payments and ongoing royalties contingent upon sales performance, providing Alkermes with a steady revenue stream and reducing its dependency on the success of any single product. By balancing its own product development with these partnerships, Alkermes secures financial robustness while maintaining its position at the forefront of pharmaceutical innovation.

ALKS Intrinsic Value
23.701 USD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Alkermes Plc's EPS (Diluted)?
EPS (Diluted)
2 USD

Based on the financial report for Sep 30, 2024, Alkermes Plc's EPS (Diluted) amounts to 2 USD.

What is Alkermes Plc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
60%

Over the last year, the EPS (Diluted) growth was 60%.

Back to Top